Market Place
Sourcing Support
Avextra Supports EU-Funded Psilocybin Study, EMA Approval Granted
12 Dec 2024 //
GLOBENEWSWIRE
Revive Therapeutics Publishes Psilocybin Stroke Approach
12 Nov 2024 //
GLOBENEWSWIRE
Dr. Michael Bogenschutz Wins $15M NIDA Grant for Psilocybin Study
31 Oct 2024 //
PR NEWSWIRE
Psyence walks away from acquisition of fellow psilocybin biotech
07 Oct 2024 //
FIERCE BIOTECH
Psyence Biomed Licenses PsyLabs` Nature-Derived Psilocybin
04 Sep 2024 //
GLOBENEWSWIRE
MindTrek`s Psilocybin Therapy Shows Positive Results For Couples On The Brink
16 Aug 2024 //
ACCESSWIRE
Apex Labs files IND with FDA for microdose psilocybin study
20 Jun 2024 //
PR NEWSWIRE
Apollomics Announces Presentation at the 2024 BIO International Convention
29 May 2024 //
GLOBENEWSWIRE
Compass tracks PTSD improvements in midphase psilocybin trial
09 May 2024 //
FIERCE BIOTECH
Optimi Health signs Psilocybin Supply Agreement
09 Apr 2024 //
GLOBENEWSWIRE
Psyence Partners with Fluence & iNGEN? CRO
08 Apr 2024 //
GLOBENEWSWIRE
Optimi Receives Product Results and COA for GMP Natural Psilocybin Extract
02 Apr 2024 //
GLOBENEWSWIRE
Revive Provides Update on Psilocybin Study for Methamphetamine Use Disorder
02 Apr 2024 //
GLOBENEWSWIRE
Rose Hill Leads the Way in Psilocybin Production
05 Mar 2024 //
GLOBENEWSWIRE
Incannex Announces Positive Results from Phase 2 Psi-GAD1 Trial of Psilocybin
28 Feb 2024 //
NASDAQ
Compass, Hackensack Meridian ink research deal for psilocybin
17 Jan 2024 //
FIERCE BIOTECH
Compass announces COMP360 psilocybin treatment was well-tolerated in ph 2 study
19 Dec 2023 //
GLOBENEWSWIRE
Terran Biosciences Receives Notice of Allowance for Four US Patents
08 Dec 2023 //
BUSINESSWIRE
Study results of psilocybin treatment in bipolar II depression published in JAMA
06 Dec 2023 //
GLOBENEWSWIRE
Compass initiates UK component of global phase 3 study of psilocybin treatment
15 Nov 2023 //
GLOBENEWSWIRE
Sunstone Announces Start of First Study of Multiple Doses of Psilocybin
06 Nov 2023 //
GLOBENEWSWIRE
Canadian Veteran Dosed with First Cycle of APEX-90 Macrodose Psilocybin
02 Nov 2023 //
PR NEWSWIRE
Reset Receives Notice of Safe to Proceed for IND Application for Psilocybin
01 Nov 2023 //
GLOBENEWSWIRE
Phyton Biotech announces acquisition of Controlled Substances Dealers License from Health Canada
29 Oct 2023 //
PRESS RELEASE
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program
11 Oct 2023 //
PR NEWSWIRE
Enveric Biosciences Expands IP Portfolio with New U.S. Patent
20 Sep 2023 //
BUSINESSWIRE
First study results of psilocybin treatment in anorexia nervosa published
25 Jul 2023 //
GLOBENEWSWIRE
Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy”
13 Jul 2023 //
GLOBENEWSWIRE
Tryp seeks FDA approval for trial of psilocybin assisted psychotherapy
25 May 2023 //
CLINICAL TRIALS ARENA
Lucy Scientific Discovery Inc. Accelerates Psilocybin Access
18 May 2023 //
GLOBENEWSWIRE
Apex Labs Granted Approval for 160 Patient Macrodose Multi-Dose Psilocybin
20 Apr 2023 //
PR NEWSWIRE
Filament Health announces FDA approval of Phase II trial studying psilocybin
16 Mar 2023 //
NEWSWIRE
Mindset and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin
06 Mar 2023 //
GLOBENEWSWIRE
Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical Trial
19 Jan 2023 //
PR NEWSWIRE
Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial
05 Jan 2023 //
ACCESSWIRE
Anorexia Nervosa Drug Pipeline Landscape: Therapeutic Assessment of Key Products
20 Dec 2022 //
BUSINESSWIRE
Psyence and Filament Announce Licensing Agreement of Psilocybin Capsule
15 Dec 2022 //
GLOBENEWSWIRE
Diamond Therapeutics completes Phase I study of low-dose psilocybin
07 Dec 2022 //
PRNEWSWIRE
Congress takes another look at reclassifying psilocybin and MDMA
18 Nov 2022 //
ENDPTS
Apex police seize 116 drug-laced candy bars and boxes of fake urine
08 Nov 2022 //
NEWSOBSERVER
Psilocybin improves depression symptoms, study shows
04 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
Tryp Therapeutics Announces Publication of International PCT Patent
03 Oct 2022 //
GLOBENEWSWIRE
Tryp Strengthens Intellectual Property PortfolioProvisional Patent Applications
26 Sep 2022 //
GLOBENEWSWIRE
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin
22 Sep 2022 //
GLOBENEWSWIRE
Origin Therapeutics’ Portfolio Company, Xpira , FDA Approval Psilocybin
22 Sep 2022 //
GLOBENEWSWIRE
UK MHRA grants approval for Psyence’s Phase IIa adjustment disorder trial
20 Sep 2022 //
CLINICALTRIALS ARENA
Revive Provides Update on the Psilocybin Clinical Study for Methamphetamine
16 Sep 2022 //
GLOBENEWSWIRE
Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian
08 Sep 2022 //
GLOBENEWSWIRE
FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED
01 Sep 2022 //
NEWSWIRE
B.More Receives FDA IND Approval for Psilocybin Alcohol Use Disorder PIIb Trial
25 Aug 2022 //
PRNEWSWIRE
Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin
10 Aug 2022 //
GLOBENEWSWIRE
COMPASS Pathways launches PII trial of psilocybin therapy in anorexia nervosa
28 Jul 2022 //
GLOBENEWSWIRE
B.More Submits FDA Investigational NDA for Psilocybin Alcohol Use Disorder
25 Jul 2022 //
PRNEWSWIRE
Bipartisan Senate bill to expand Right to Try into MDMA and psilocybin
22 Jul 2022 //
ENDPTS
Optimi Health Finalizes Psilocybin Supply Agreement
13 Jul 2022 //
GLOBENEWSWIRE
Optimi Health Sighns Agreement With SABI Mind For Supplies Of Psilocybin, MDMA
28 Jun 2022 //
GLOBENEWSWIRE
Ceruvia Lifesciences Receives IND Approval for Psilocybin OCD Program PII Trial
27 Jun 2022 //
PRNEWSWIRE
Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health
31 May 2022 //
GLOBENEWSWIRE
Lennham bags U.S. Patent Covering Methods of Administering Psilocybin & Psilocin
31 May 2022 //
BUSINESSWIRE
